

TABLE 2b. Seroconversion Assessment, Prospective Cohort

Sample ID	Pre-deployment	Post-deployment	Fold change	MNA titer
142	15.59	15.43	0.99	0
195	7.62	10.94	1.43	0
196	15.69	13.38	0.85	0
197	12.69	12.17	0.96	0
247	20.70	15.32	0.74	20
249	8.77	10.68	1.22	0
262	10.41	12.66	1.22	0
280	10.20	12.85	1.26	0
303	13.64	13.94	1.02	0
17	11.30	10.53	0.93	0
25	16.50	15.52	0.94	0
26	12.58	10.97	0.87	0
57	9.50	14.34	1.51	0
59	1.90	9.62	5.06	0
63	6.01	16.40	2.73	0
66	15.84	14.22	0.90	0
91	12.33	12.51	1.01	0
95	6.22	12.00	1.93	0
112	7.12	10.08	1.42	0
116	5.73	9.31	1.62	0
128	8.95	9.87	1.10	0
309	20.47	19.91	0.97	0
317	16.48	16.23	0.98	0
325	8.18	11.29	1.38	0
331	15.05	12.37	0.82	0
333	13.04	11.27	0.86	0
342	7.34	11.24	1.53	0
347	12.27	13.30	1.08	0
352	12.24	15.49	1.27	0
399	10.20	10.40	1.02	0
407	13.00	11.63	0.89	0
420	9.11	9.85	1.08	0

Abbreviation: MNA, micro-neutralization assay.

Note: Each prospective cohort post-deployment sample that tested positive or equivocal (≥ 9 PBUs) was paired with its pre-deployment sample and retested. The pre- to post-deployment titer fold change is listed, as well as the MNA titer for each post-deployment sample.